Public Biotech 2010—the Numbers

Gossamer Bio became San Diego’s newest publicly traded company this week, bringing in a hefty haul of $276 million in its initial public offering. The offering indicated that the bull market for biotech, prevalent during last year, continues.

The biotech company is led by veterans of multiple sclerosis drug developer Receptos, purchased in 2015 for $7.3 billion. It had originally planned to sell enough shares at $16 apiece to raise $230 million, but raised the number because demand was higher than expected.

Gossamer began trading Friday on Nasdaq under the ticker GOSS. Shares began the day at $19 each, up from the $16 IPO price reached late Thursday. Shares closed at $17.94, up $1.94 for the day.

Gossamer's IPO price, and Friday’s closing price, value the company at more than $1 billion. That status is also shared by another biotech, San Francisco’s Alector, which began trading on Thursday.

Source :

Gossamer Bio goes public; San Diego biotech valued at more than $1 billion
Biotech firm wins public cash to develop fungal treatment
"Future Leaders in the Biotech Industry" Attracts Standing Room Only Audience
Venture Capital Flows to Biotech as Public Financing Takes a Breather
ExpreS2ion Biotech Holding AB: Last day of trading in BTA
Islay backs biotech boom to push Worldwide Healthcare Trust
Can Biotechnology Solve China’s Food Security Problem?
You Shouldn’t Fear Do-It-Yourself Biotech
Cover Story: Global Biotech Report
Portola Pharmaceuticals: A Biotech Company With Plenty Of Room To Grow